Engineering Novel Biologics with Precision Targeting

Conferences Include:

May 11-12

Display of Biologics

May 12-13

Engineering Antibodies

May 14-15

Machine Learning Approaches for Protein Engineering

Keynote and Featured Speakers:

History of Checkpoint Blockade Therapy for Cancer
Nils Lonberg, PhD, CEO, Tripeaks Therapeutics; Executive in Residence, Canaan Partners

Fifty Years of Monoclonals: From Hybridomas to Next-Generation Antibody Therapeutics
Paul J. Carter, PhD, Genentech Fellow, Antibody Engineering, Genentech

Unbiased Deep Screening of Antibody-Antigen Interactions
Timothy A. Whitehead, PhD, Professor, Chemical & Biological Engineering, University of Colorado, Boulder

2026 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multispecific Antibodies

• Emerging T Cell Engagers
• Advances in Immunotherapy
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Bioassay Development and Analysis

• Biologics for Autoimmune Diseases
• Frontiers in Radiopharmaceutical Therapy
• Emerging Peptide Therapeutics

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering